STOCK TITAN

Cryo-Cell International, Inc. - CCEL STOCK NEWS

Welcome to our dedicated news page for Cryo-Cell International (Ticker: CCEL), a resource for investors and traders seeking the latest updates and insights on Cryo-Cell International.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cryo-Cell International's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cryo-Cell International's position in the market.

Rhea-AI Summary
Cryo-Cell International, Inc. (CCEL) reported fiscal first quarter 2024 financial results with revenues of $7.85 million, a slight increase from the previous year. Net income was approximately $556,000, down from $767,000 in 2023 due to higher expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.37%
Tags
-
Rhea-AI Summary
Cryo-Cell International, Inc. (CCEL) announces the spin-off of its subsidiary, Celle Corp., to maximize shareholder value. Celle Corp. will hold assets not related to cord blood banking, including the Patent and Technology License Agreement with Duke University. The spin-off is expected to occur in the 2nd or 3rd fiscal quarters.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.64%
Tags
none
-
Rhea-AI Summary
Cryo-Cell International, Inc. (CCEL) announced fiscal year 2023 results with $31.3 million in revenues. The company reported a net loss of $9.5 million due to non-cash charges. Despite this, they plan to transfer assets to a subsidiary for financial flexibility.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.97%
Tags
Rhea-AI Summary
Cryo-Cell International, Inc. announces Q3 2023 results with a 2% increase in revenue and a net income of $681,000.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.18%
Tags
-
Rhea-AI Summary
Cryo-Cell International, Inc. (NYSE American LLC: CCEL) reported a 2% increase in revenue for the fiscal second quarter of 2023 compared to the same period last year. Net income for the quarter was $220,976, down from $634,719 in the previous year. The increase in revenue was driven by higher processing and storage fee revenue, while the decrease in net income was primarily due to increased research and development expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.38%
Tags
dividends
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.65%
Tags
none
Cryo-Cell International, Inc.

NYSE:CCEL

CCEL Rankings

CCEL Stock Data

59.75M
4.46M
46.18%
10.57%
0.26%
Dental Laboratories
Manufacturing
Link
US
Oldsmar

About CCEL

founded in 1989, cryo-cell is the oldest cord blood bank and was the first cord blood bank to separate and store stem cells in 1992. today, the company has over 270,000 clients worldwide. since inception, 100% of our clients’ specimens have been successfully viable upon thaw. our services include umbilical cord blood, cord tissue and menstrual stem cell banking. cryo-cell operates its own state-of-the-art processing, testing and cryopreservation operation. we are in complete control of every step, ensuring the highest quality available today.